AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
|
27 November 2017 |
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
|
15 November 2017 |
FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
|
31 October 2017 |
FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
|
18 October 2017 |
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
|
11 October 2017 |
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
|
25 September 2017 |
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
|
12 September 2017 |
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
|
06 September 2017 |
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
|
29 August 2017 |
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
|
24 August 2017 |